

O/K & enter

EPA 9/28/07

Appl. No. 10/775,423
Amdt. dated September 5, 2007
Reply to Final Office Action of July 11, 2007

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

Amendments to the Claims:

Claims 1-20 (canceled)

Claim 21 (currently amended) An isolated or purified polypeptide having at least 90% sequence identity to an extracellular domain of SEQ ID NO: 12 or 14, wherein the polypeptide associates with a DAP12 polypeptide having the amino acid sequence of SEQ ID NO: 2 or 6.

Claim 22 (currently amended) The isolated or purified polypeptide of claim 21, wherein the polypeptide has at least 95% sequence identity to the extracellular domain of SEQ ID NO: 12 or 14, wherein the polypeptide associates with a DAP12 polypeptide having the amino acid sequence of SEQ ID NO: 2 or 6.

Claim 23 (canceled)

Claim 24 (previously presented) The isolated and purified polypeptide of claim 21 fused to a heterologous protein.

Claim 25 (previously presented) The isolated and purified polypeptide of claim 24, wherein the heterologous protein is an immunoglobulin peptide.

Claim 26 (previously presented) The isolated and purified polypeptide of claim 24, wherein the heterologous protein is a detection or purification tag selected from the group consisting of a FLAG, His6, β -galactosidase, trpE, Protein A, β -lactamase, alpha amylase, alcohol dehydrogenase, and yeast alpha mating factor.

Claim 27 (previously presented) A composition comprising the isolated and purified polypeptide of claim 21 and a pharmaceutically acceptable carrier.